Ombrabulin

Summary

Ombrabulin (CHEMBL572284) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including sarcoma and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 11
• Chemistry: 402.4 Da · C21H26N2O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL572284
Name	Ombrabulin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918405
Molecular formula	C21H26N2O6
Molecular weight	402.4
InChIKey	IXWNTLSTOZFSCM-YVACAVLKSA-N

SMILES: COC1=C(C=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)NC(=O)[C@H](CO)N

IUPAC name: (2S)-2-amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide

Also known as: AC7700, AVE-8062, Ave8062, AVE8062, Ombrabulin, Ombrabulina, Ombrabuline, OMBRABULIN

Parent form; salt/anhydrous children: CHEMBL585539

Patent coverage: 473 distinct patent families (1,132 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,129 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Tubulin.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sarcoma	3	MONDO:0005089	EFO:0000691
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
ovarian cancer	2	MONDO:0008170	MONDO:0008170
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE1	8
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00699517	PHASE3	COMPLETED	A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
NCT01263886	PHASE2	COMPLETED	Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
NCT01332656	PHASE2	COMPLETED	Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
NCT00719524	PHASE1	COMPLETED	AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
NCT00968916	PHASE1	COMPLETED	Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors
NCT01021150	PHASE1	COMPLETED	Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors
NCT01063946	PHASE1	COMPLETED	A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
NCT01095302	PHASE1	COMPLETED	Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
NCT01193595	PHASE1	COMPLETED	Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
NCT01293630	PHASE1	COMPLETED	A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
NCT01907685	PHASE1	COMPLETED	Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).